Inflammation key to severe COVID-19 in high-risk groups: Study
Only certain patients likely to benefit from antibody-rich plasma
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Latest Updates
Rentschler Biopharma and Vetter team up to simplify processes and optimize time-to-market
The desired goal of the collaboration is to create long-term value through the alignment of manufacturing approaches that enable…
UP govt asks suggestions from stakeholders to frame its pharma policy
The state government has identified 2000 acres of land each in Pilibhit and Lalitpur, Bundelkhand for bulk drugs and medical…
WHO reviewing report urging new guidance over airborne spread of coronavirus
How frequently the coronavirus can spread by the airborne or aerosol route - as opposed to by larger droplets in coughs and…
The rise in talent demand will be for specialist functions like R&D, trials and approvals
Manu Saigal, Director, General Staffing, Adecco India informs that Indian operations of Randstad, The Adecco Group, Manpower…
Immune Regulation and DynPort Vaccine Company partner to advance COVID-19 drug in clinical trials
Immune Regulation’s drug candidate IRL201104 has been shown to quickly and markedly reduce excessive infiltration of neutrophils…
Mylan to launch DESREM at Rs 4800 per vial
Mylan will manufacture remdesivir in India at its injectables facilities, which also make product for the US.
Mankind Pharma promotes ‘Atmanirbhar Bharat’ with new anthem
The anthem underlines some of the greatest achievements and innovations of the nation in the field of science, technology, health,…
WHO halts hydroxychloroquine, HIV drugs in COVID trials after failure to reduce death
The setback came as the WHO also reported more than 200,000 new cases globally of the disease for the first time in a single day
Zydus gets nod from COFEPRIS, Mexico to study Desidustat for COVID-19 management
As a part of the study, 100 mg tablets of Desidustat will be administered for a period of 14 days along with recommended standard…
Britain nears $625 million Sanofi/GSK COVID-19 vaccine deal: report
Clinical trials are due to start in September and Sanofi has said it expects to get approval by the first half of next year,…
Experts ask govt to ensure access to remdesivir, raise concerns about supply shortage
Many also allude to an emerging black market for remdesivir in the country through which the drug is being sold at exorbitant…
Hundreds of scientists say coronavirus is airborne, ask WHO to revise recommendations: NYT
The WHO has said the coronavirus disease spreads primarily from person to person through small droplets from the nose or mouth
Skilled life sciences specialists give India an edge in times of a pandemic
Ranjit Madan, CEO, LSSSDC, outlines the role and vision of his organisation to skill the workforce in life sciences and informs…
Indian pharma firms recall medications from US market
Lupin and Marksans Pharma recall diabetes drugs while Alembic and Aurbindo recall medicines that treat mental disorders
WHO to discontinue hydroxycholorquine trial for COVID-19
It said interim results show hydroxychloroquine “produce little or no reduction in the mortality of hospitalised COVID-19 patients…
New COVID-19 strain dominates global cases of virus, it is more infectious but not more severe
The variant, named ‘D614G’, makes a small but effective change in the ‘spike’ glycoprotein that protrudes from the surface of the…
ICMR defends COVID-19 vaccine deadline
In a statement, ICMR says that its process is in accordance with globally accepted norms to fast-track vaccine development for…
Astrazeneca’s Dapagliflozin gets DCGI nod for treatment of heart failure
Dapagliflozin (Forxiga) is an SGLT-2 inhibitor that can reduce the risk of cardiovascular death and hospitalisation for heart…
Stevioside can increase efficiency of cancer therapy using magnetic nano particles: Scientists
Coating nanoparticles with stevioside improved the cellular uptake of the nano-magnets in glioma C6 cancer cells and enhanced its…